ArticleMovement disorders : official journal of the Movement Disorder Society2018
Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.
Article in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis.Frontiers in neuroscience · 2020Pooled it
- Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.Molecular psychiatry · 2026Article
- Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Sex differences for clinical presentations and co-pathologies in four-repeat tauopathies.Biology of sex differences · 2026Article
- Patterns and causes of supranuclear vertical gaze palsy: A retrospective, single-institutional study in 113 patients.Clinical parkinsonism & related disorders · 2025Article
- Prospective longitudinal cohort of Argentinean patients with progressive supranuclear palsy and corticobasal syndrome: A platform for epidemiological and translational research.Clinical parkinsonism & related disorders · 2025Article
- Sex hormones, body mass index, and related comorbidities associated with developing Sjögren's disease: a nested case-control study.Clinical rheumatology · 2022Article
- Environmental Risk Factors for Progressive Supranuclear Palsy.Journal of movement disorders · 2021Article
- Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.Frontiers in molecular neuroscience · 2021Review
- Progressive Supranuclear Palsy and Corticobasal Degeneration.Advances in experimental medicine and biology · 2021Article
- Association of Sjögren's Syndrome With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study.Arthritis care & research · 2020Article
- Progressive supranuclear palsy: Advances in diagnosis and management.Parkinsonism & related disorders · 2020Review
- Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.Scientific reports · 2019Article
- Frontrunner in Translation: Progressive Supranuclear Palsy.Frontiers in neurology · 2019Review
- Symptoms, Lifetime Duration of Estrogen Exposure, and Ovarian Reserve Among Women Living With HIV: A Cross-Sectional Observational Study.The Journal of the Association of Nurses in AIDS Care : JANACObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 3 countries.
Funding
Abstract
backgroundStudies suggesting a protective effect of estrogen in neurodegenerative diseases prompted us to investigate this relationship in progressive supranuclear palsy (PSP).
methodsThis case-control study evaluated the self-reported reproductive characteristics and estrogen of 150 women with PSP and 150 age-matched female controls who participated in the Environmental Genetic-PSP study. Conditional logistic regression models were generated to examine associations of PSP with estrogen.
resultsThere was no association between years of estrogen exposure duration and PSP. There was a suggestion of an inverse association between composite estrogen score and PSP that did not reach statistical significance (P = .06). Any exposure to estrogen replacement therapy halved the risk of PSP (odds ratio = 0.52; 95% confidence interval = 0.30-0.92; P = .03). Among PSP cases, earlier age at menarche was associated with better performance on Hoehn and Yahr stage (β = -0.60; SE = 0.26; P = .02) and Unified Parkinson's Disease Rating Scale II score (β = -5.19; SE = 2.48; P = .04) at clinical examination.
conclusionsThis case-control study suggests a protective role of lifetime estrogen exposure in PSP. Future studies will be needed to confirm this association. © 2018 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.